Posted in | News

Evonik launches EUDRAGIT® FL 30 D-55, an advanced combination polymer that sets a new benchmark for enteric coatings

Evonik launches EUDRAGIT® FL 30 D-55, an advanced combination polymer that sets a new benchmark for enteric coatings

  • Highly-flexible polymer enabling plasticizer-free formulations
  • New proprietary manufacturing technology combines the benefits of two pharmacopoeial polymers
  • Easy-to-process, with spray suspension preparation times reduced by up to 70%
  • Thin films allow for increased drug loads with multiparticulates

Evonik, a global leader for functional excipients used in oral solid dosage forms, today announced the launch of an advanced combination polymer for enteric coatings.

EUDRAGIT® FL 30 D-55 leverages Evonik’s new, proprietary AEMP® technology (Advanced Excipient Manufacturing Process) to combine the respective benefits of two well-established and monographed polymers including EUDRAGIT® L 30 D-55.

EUDRAGIT® FL 30 D-55 is a highly flexible polymer that enables plasticizer-free formulations, making it ideal for the compression of coated multiparticulates. It can be sprayed with a smooth, fast and no-stick process for excellent adhesion. As a single product, spray suspension preparation times can be reduced by up to 70%, while lowering manufacturing costs and total required polymer volumes. It has also been shown to reduce coating film thicknesses, creating opportunities for increased drug loading.

“As the first ever excipient based upon our proprietary AEMP® technology, EUDRAGIT® FL 30 D-55 combines the best features of two well-accepted polymers including EUDRAGIT® L 30 D-55, which has been the gold standard for enteric coatings for decades,” said Paul Spencer, Global Head of Oral Drug Delivery Solutions for the Health Care business line of Evonik. “This high-tech excipient features extremely high flexibility even without plasticizers. EUDRAGIT® FL 30 D-55 sets a new standard for enteric coatings to help customers reduce processing complexity, lower preparation times and save costs.”

Companies seeking more information about EUDRAGIT® FL 30 D-55 can visit the Evonik booth 9K20 at CPhI Worldwide in Madrid from October 9 to 11, or AAPS PharmSci 360 in Washington D.C. from November 4 to 7 at booth 2127. Requests for individual meetings or product samples can be made via [email protected].

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evonik Industries AG. (2018, October 05). Evonik launches EUDRAGIT® FL 30 D-55, an advanced combination polymer that sets a new benchmark for enteric coatings . AZoM. Retrieved on April 24, 2024 from https://www.azom.com/news.aspx?newsID=49764.

  • MLA

    Evonik Industries AG. "Evonik launches EUDRAGIT® FL 30 D-55, an advanced combination polymer that sets a new benchmark for enteric coatings ". AZoM. 24 April 2024. <https://www.azom.com/news.aspx?newsID=49764>.

  • Chicago

    Evonik Industries AG. "Evonik launches EUDRAGIT® FL 30 D-55, an advanced combination polymer that sets a new benchmark for enteric coatings ". AZoM. https://www.azom.com/news.aspx?newsID=49764. (accessed April 24, 2024).

  • Harvard

    Evonik Industries AG. 2018. Evonik launches EUDRAGIT® FL 30 D-55, an advanced combination polymer that sets a new benchmark for enteric coatings . AZoM, viewed 24 April 2024, https://www.azom.com/news.aspx?newsID=49764.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.